De Novo Urological Malignancies After Renal Transplantation: An Asian 30‐Year Experience
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Han Jie Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Kidney Transplantation, Urologic Neoplasms, Postoperative Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
As the incidence of urological malignancies after renal transplantation (RT) is observed to be greater than in the general population, a better understanding of them is important. We present our experience with urological tumors in RT recipients at our transplant center, and analyze their incidence, management and outcomes. Materials and Methods A retrospective analysis of 2177 RT recipients on follow‐up at our center between 1990 and 2022 was conducted for de novo genitourinary malignancy. Patients diagnosed with malignancy before transplantation were excluded. Clinicopathological data at diagnosis and follow‐up were collected and analyzed. Kaplan‐Meier estimates were used to evaluate overall survival (OS) and cancer‐specific survival (CSS). Statistical analysis was performed using IBM SPSS v.24 (IBM Corp., Armonk, NY, USA).
Results
The overall incidence of Urological malignancies was 3.9%, with 89 cancers diagnosed in 85 patients. Renal cell carcinoma was most common ( n = 61, 68.5%), followed by prostate cancer ( n = 10, 11.2%), urothelial carcinoma ( n = 10, 11.2%), squamous cell carcinoma of the penis/scrotum ( n = 7, 7.9%), and testicular cancer ( n = 1, 1.1%). Mean duration between transplantation and diagnosis of malignancy was 9.9 (0.4–20.7) years. At a median follow‐up of 4.6 (018.2) years, 27 deaths were seen; 7(25.9%) were due to urological malignancy. CSS rates were 86% and 78% at five and ten years, respectively, after diagnosis.
Conclusion
We present one of the largest series of de novo urological malignancies observed over an extended 30‐year follow‐up of RT recipients, demonstrating an elevated risk in line with other studies. Regular surveillance for malignancies is advised, in order to ensure early diagnosis and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Singapore General Hospital, Singapore, Singapore.
- Singhealth Duke-NUS Transplant Centre, Singapore, Singapore.
ORCID-Profile: Han Jie Lee
Zitieren
APA
Lee, H. J., Lim, E. J., Woo, S. J. Q., Aslim, E. J., Ng, L. G., & Gan, V. H. L. (2024). De Novo Urological Malignancies After Renal Transplantation: An Asian 30‐Year Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.15415
Vancouver
Lee HJ, Lim EJ, Woo SJQ, Aslim EJ, Ng LG, Gan VHL. De Novo Urological Malignancies After Renal Transplantation: An Asian 30‐Year Experience. Clinical Transplantation. 2024. doi:10.1111/ctr.15415
BibTeX
@article{Lee2024,
author = {Lee, Han Jie and Lim, Ee Jean and Woo, Shauna Jia Qian and Aslim, Edwin J and Ng, Lay Guat and Gan, Valerie Huei Li},
title = {De Novo Urological Malignancies After Renal Transplantation: An Asian 30‐Year Experience},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15415}
}
EUVIMED